You can view a presentation of ASH from a myeloma specialist’s perspective if you CLICK HERE. Dr. Orlowski of MD Anderson and Dr. Richardson of Dana Farber, two of the most skilled myeloma practitioners in the world give you their takeaways from the meetings. Pat Killingsworth provided a blog post on this presentation and includes a lively discussion by his readers, and you can read it if you CLICK HERE.
Some of the biggest news that the panel members gleaned from the meeting include:
– They were all excited about the number of doctors who are now talking of CURE of low risk disease…in the next 5 years.
– Continued focus on Monoclonal antibodies like Daratumumab and SAR650984 which showed single agent results in heavily pretreated patients.
– Fit/Unfit/Frail categories for elderly
– SMM (Smoldering) Risk analysis & early treatment
– Cytoxin benefit over Melphalan
– So many treatment options now with Cfz and Pom and available clinical trials
– Maintenance still needs more study
– Buzz around Black Swan initiative and Onyx
– Maintenance vs. non-maintenance post transplant
– Top 8 new drugs – anti CD38, MLN9708, ARRY 520, ACY 1215, Selinexor, antiCD138, panobinostat, bendamustine
– Immunotherapies (daratumumab and CD138)
– Compass Trial
– Daratumumab, Revlmid, dex combination showed impressive results with a response rate of 73% in a small population of patients (8/11 patients who had received a median of 3-4 prior treatments)
– Novartis/Penn’s customized T cell wows ASH with stellar leukemia data – A total of 19 of 22 pediatric patients with lethal cases of acute lymphoblastic leukemia experienced complete remissions after being treated with the CAR T therapy, CTL019, a T cell engineering to target cancer cells that express the CD19 protein. And they say it may have application for myeloma!
The one disappointment for me was the lack of any trials with an IMID, proteasome inhibitor, steroid, and monoclonal antibody such as RVd with Daratumumab.
Pictures of the Panel Members are shown below. Our own MYELOMA POWER RANGERS. Thank you so much for all you do for the multiple myeloma patient community.